RxDoctor Payments Data

Todd Miller, MD

Otolaryngology · Newport Beach, CANPI 1033387931

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.8%), grants and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 93.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $92,054 and has fallen 80.2% since, to $18,206 in 2025. Among otolaryngology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$258,959in general payments, 2019–2025

Across 303 payments — averaging $854.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$243K
  • Merz North America, Inc.$7K
  • Stryker$4K
  • Inspire Medical Systems, Inc.$3K
  • Sanofi$624
  • GSK$471
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$1,4251%
  • Speaking & faculty fees$147,14657%
  • Grants$94,92537%
  • Travel & lodging$6980%
  • Food & beverage$14,7316%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,959 in reported general payments places this provider in the 95th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$533,297
Medicare patients
1,167
Services billed
6,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth91$9,749
Ipratropium Bromide115$4,754
Fluticasone Propionate186$2,372
Fluocinolone Acetonide Oil36$1,310
Azelastine Hcl38$1,093
Omeprazole132$1,050
Famotidine167$897
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav82$835
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort17$812
Methylprednisolone61$423
Montelukast Sodium39$295
Doxycycline Hyclate32$286
Clindamycin Hcl22$242
Promethazine Hcl16$226
Meclizine Hcl14$212

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →